Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report

Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report

Nivolumab, an anti-programmed death-1 (PD-1) receptor monoclonal antibody, has proven effective in treating platinum-resistant metastatic head and neck squamous cell carcinoma. Immune-related adverse events (irAEs) are well-known complications of PD-1 inhibitors. Meanwhile, cytokine release syndrome...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomoyuki Otsuka, Yoshiki Kojitani, Fumio Imamura, Junko Fukutake, Minako Nishio, Takashi Fujii, Toshihiro Kudo
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitor
immune-related adverse event
cytokine release syndrome
head and neck squamous cell carcinoma
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1508682/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items